Obatoclax mesylate
| Title | Journal |
|---|---|
| Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. | The Journal of biological chemistry 20121012 |
| Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists. | European journal of medicinal chemistry 20121001 |
| CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. | Cancer research 20120815 |
| A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. | Cancer letters 20120801 |
| Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. | Leukemia 20120701 |
| Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. | Cell death & disease 20120701 |
| Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. | Blood 20120621 |
| Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. | Cancer research 20120615 |
| Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. | Blood 20120503 |
| Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. | Molecular pharmacology 20120501 |
| Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. | Molecular cancer therapeutics 20120501 |
| Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. | Molecular pharmacology 20120401 |
| Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms. | Expert opinion on investigational drugs 20120301 |
| Protein-protein interaction inhibitors get into the groove. | Nature reviews. Drug discovery 20120301 |
| Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. | Blood 20120301 |
| A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. | British journal of cancer 20120227 |
| Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. | Biochemical pharmacology 20120215 |
| Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells. | Pediatric surgery international 20120201 |
| Bcl-2 inhibitors: emerging drugs in cancer therapy. | Current medicinal chemistry 20120101 |
| Synthetic prodiginine obatoclax (GX15-070) and related analogues: anion binding, transmembrane transport, and cytotoxicity properties. | Chemistry (Weinheim an der Bergstrasse, Germany) 20111209 |
| The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. | Experimental hematology 20111001 |
| Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. | Pathology 20111001 |
| Molecular dynamics study of small molecule inhibitors of the Bcl-2 family. | Proteins 20110901 |
| Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. | Cell cycle (Georgetown, Tex.) 20110815 |
| Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. | British journal of haematology 20110601 |
| Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. | Neoplasia (New York, N.Y.) 20110401 |
| Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. | Apoptosis : an international journal on programmed cell death 20110301 |
| VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. | Molecular therapy : the journal of the American Society of Gene Therapy 20101201 |
| Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. | Cell death & disease 20101201 |
| A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. | Cancer chemotherapy and pharmacology 20101101 |
| Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. | Cancer biology & therapy 20101101 |
| The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. | Autophagy 20101001 |
| Drugs targeting Bcl-2 family members as an emerging strategy in cancer. | Expert reviews in molecular medicine 20100908 |
| The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. | Blood 20100902 |
| GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. | Cell death & disease 20100901 |
| The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100801 |
| Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100801 |
| Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. | Clinical lymphoma, myeloma & leukemia 20100801 |
| Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age? | Expert review of hematology 20100801 |
| The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. | Cancer letters 20100728 |
| Targeting mitochondria for cancer therapy. | Nature reviews. Drug discovery 20100601 |
| Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. | The Journal of clinical investigation 20100401 |
| A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. | Cancer research 20100301 |
| New insights on the antitumoral properties of prodiginines. | Current medicinal chemistry 20100101 |
| Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. | Cancer biology & therapy 20091101 |
| Autophagy can contribute to cell death when combining targeted therapy. | Cancer biology & therapy 20091101 |
| Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. | Neoplasia (New York, N.Y.) 20090901 |
| Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. | Blood 20090108 |
| Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. | Journal of cellular physiology 20090101 |
| BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090101 |
| A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081215 |
| Mimicking the BH3 domain to kill cancer cells. | Oncogene 20081201 |
| BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention. | Oncogene 20081201 |
| Bcl-2 family members as molecular targets in cancer therapy. | Biochemical pharmacology 20081015 |
| BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. | Leukemia 20080901 |
| BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. | Molecular cancer therapeutics 20080801 |
| Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. | Clinical lymphoma & myeloma 20080801 |
| Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). | Cancer research 20080501 |
| A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. | Cancer chemotherapy and pharmacology 20080301 |
| Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. | Leukemia 20080301 |
| Molecule of the month. Elesclomol and obatoclax mesylate. | Drug news & perspectives 20080301 |
| Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. | Blood 20070615 |
| The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. | Blood 20070515 |
| Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. | Oncology reports 20070201 |
| Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. | Experimental hematology 20061201 |
| Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. | Hematology. American Society of Hematology. Education Program 20050101 |